Company Intelligence Profile
Kimia Biosciences Limited
Haryana-based BSE-listed pharmaceutical API/KSM manufacturer with an emerging CDMO/CRO services business.
Last updated 20 August 2026
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
Company Identity
Confirmed| Registered name | Kimia Biosciences Limited |
|---|---|
| CIN | L24239HR1993PLC032120 |
| PAN | Not available in the public sources reviewed. |
| Status | Active |
| Listing | Yes — BSE: 530313 (SME/mainboard equity, actively traded). [Source: TheCompanyCheck] |
| Incorporated | 27 September 1993 (as Laurel Organics Limited / Dolphin Organics Limited, later renamed Kimia Biosciences Limited). [Sources: Tofler, TheCompanyCheck — agree] |
| ROC | RoC Haryana |
| Sector (NIC) | Pharmaceuticals — API (Active Pharmaceutical Ingredients) manufacturing, Commercial KSMs/Intermediates/Reagents, and CRAM/CDMO/CRO services. NIC 24239 = Manufacture of pharmaceuticals, medicinal chemical and botanical products. [Source: TheCompanyCheck, screener.in] |
| Registered address | Village Bhondsi, Tehsil Sohna, Bhondsi, Gurgaon, Haryana, India – 122102. [Sources: Tofler, TheCompanyCheck — agree] |
| Authorized capital | ₹16.39–16.4 Cr [Sources: Tofler, TheCompanyCheck — agree] |
| Paid-up capital | Conflicting figures: Tofler states ₹4.7 Cr |
Business Overview
Confirmed- Pharmaceutical manufacturer established 1993, operating in Active Pharmaceutical Ingredients (APIs), Commercial KSMs (Key Starting Materials)/Intermediates/Reagents, and an emerging CRAM/CDMO/CRO (contract research & manufacturing) services business
- Exports to 30+ countries
- ISO 9001:2015 certified
- ~229 employees (Apr 2024). [Sources: TheCompanyCheck, screener.in, kimiabiosciences.com]
Directors
Partial / conflictingCurrent board per TheCompanyCheck (more recent, appointment dates given) with DINs per Tofler (DINs not independently re-verified against TheCompanyCheck's more current roster — partial confidence):
| Name | DIN | Role | Appointed |
|---|---|---|---|
| Jagdeep Dhawan | 00778235 | Director | 29 Mar 2016 |
| Sameer Goel | 00161786 | Managing Director/Shareholder | 29 Mar 2016 |
| Richa Gupta | 07481646 | Director | 15 Apr 2016 |
| Vipul Goel | 00064274 | Director/Shareholder; unconfirmed) | - |
| Vijaya Sekhar Reddy Kaku | - | Additional Director appointed 29 Dec 2025 | 29 Dec 2025 |
| Naveen Sharma | - | CFO KMP, not director appointed 10 Jan 2026 | 10 Jan 2026 |
Financials
Partial / conflictingFY2025 (year ended 31 Mar 2025) standalone, per TheCompanyCheck: Revenue ₹120.24 Cr (+13% YoY); EBITDA and PAT not disclosed (paywalled). Per screener.in (Mar 2026 annual / TTM basis, likely consolidated/latest trailing): Revenue ₹115 Cr, Net Profit ₹7 Cr, Operating Margin 12%, Net Worth ~₹18 Cr (equity+reserves, screener flags this as thin relative to book), Total Borrowings ₹35 Cr, Total Assets ₹103 Cr, Market Cap ₹133 Cr, P/E 18.5x, P/B 7.52x, ROE (3-yr) 53.6%, ROCE 25.1%. 5-year revenue CAGR -3%, 3-year CAGR -4% (declining trend flagged by screener). No dividend paid. TheCompanyCheck's FY2025 revenue (₹120.24 Cr) vs screener's FY2026 figure (₹115 Cr) differ by period — not a direct contradiction, but neither source's EBITDA/PAT for FY2025 could be cross-verified against a second source, so financials are rated partial confidence.
Charges & Loans
Partial / conflicting- Open charges ₹32.11 Cr
- Satisfied charges ₹111.62 Cr. Major lender: HDFC Bank Limited (₹1.26 Cr charge), Others (₹30.85 Cr)
- Total borrowings per screener.in: ₹35 Cr (broadly consistent with open-charge figure)
- Single primary source for charge-level detail — partial confidence
Legal (Indian Kanoon)
Partial / conflicting- Indian Kanoon search shows multiple customs/excise litigation matters, predominantly "Kimia Biosciences Limited vs Union of India" before the Delhi High Court (2020, 2021, 2022, 2023) — pattern consistent with recurring customs/import duty disputes typical for an API manufacturer
- Also: Mandeep Kaur Jaggi vs M/S Kimia Biosciences Ltd (Punjab-Haryana HC, 25 Apr 2024) — nature not detailed here (likely a service/labour or civil matter)
- C.C
- (Import & General), New Delhi vs M/S Kimia Biosciences (P) Ltd (CESTAT, 13 Jan 2016)
- and two National Green Tribunal matters "Surendar Kumar Sharma vs State of Haryana" (2022) that reference the company's location/operations context, exact nexus not confirmed. [Source: indiankanoon.org]
Competitors
ConfirmedIndian pharma API/CDMO peers (varying scale — Kimia is a small-cap at ~₹133 Cr market cap and ~₹115-120 Cr revenue):
- Aarti Drugs Ltd — large-cap API manufacturer (much larger scale)
- Neuland Laboratories Ltd — mid-cap CDMO/API player (larger scale)
- Suven Pharmaceuticals Ltd — mid/large-cap CDMO (larger scale)
- Laurus Labs Ltd — large-cap API/CDMO (much larger scale)
- Divi's Laboratories Ltd — large-cap API leader (much larger scale)
- Shilpa Medicare Ltd — mid-cap API/specialty pharma (larger scale)
these are broad sector peers by business model (API/KSM/CDMO); Kimia is materially smaller in revenue and market cap than all listed above.
Frequently Asked Questions
What does Kimia Biosciences Limited do?
What is the CIN of Kimia Biosciences Limited?
Where is Kimia Biosciences Limited registered?
When was Kimia Biosciences Limited incorporated?
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.